LOS ANGELES – (AP) A unit of Johnson & Johnson said Monday that a federal jury has ordered Abbott Laboratories to pay $1.67 billion in a patent infringement suit over the companies' rheumatoid arthritis drugs.
Abbott's best-selling drug, Humira, competes with the drug Remicade, an anti-TNF class of arthritis treatments made by J&J's Centocor . . . .
Subscribers to www.lexis.com may read the full version of this article here.